Translational research in head and neck cancer: Biological characteristics and general aspects;Translationale Forschung bei Kopf-Hals-Tumoren: Biologische Besonderheiten und generelle Problematik

HNO

Volumn 59, Issue 9, 2011, Pages 874-884

  Dietz, A ^a   Wichmann, G ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Biological specimen banks; Correlated gene sets; Head and neck neoplasms; Squamous cell carcinoma of the head and neck; Translational research

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MTOR PROTEIN, HUMAN; PROTEIN P53; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ARTICLE; CANCER STAGING; CELL TRANSFORMATION; CHROMOSOME DELETION; DISEASE FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; HEALTH CARE FACILITY; HUMAN; MASS SPECTROMETRY; MORTALITY; MULTIMODALITY CANCER THERAPY; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TRANSLATIONAL RESEARCH;

BIOLOGICAL MARKERS; BIOLOGICAL SPECIMEN BANKS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CHEMORADIOTHERAPY, ADJUVANT; CHROMOSOME DELETION; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TOR SERINE-THREONINE KINASES; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80052274365     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-011-2361-5     Document Type: Article

References (55)

1. Andl T, Kahn T, Pfuhl A et al (1998) Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 58(1): 5-13.
2. Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1): 24-35.
3. Baylin SB, Herman JG (2001) Promotor hypermethylation - can this change alone ever designate true tumor suppressor gene function? J Natl Cancer Inst 93: 664-665.
4. Binder H, Brücker J, Burden CJ (2009) Nonspecific hybridization scaling of microarray expression estimates: a physicochemical approach for chip-to-chip normalization. J Phys Chem B 113(9): 2874-2895.
5. Binder H, Fasold M, Glomb T (2009) Mismatch and G-stack modulated probe signals on SNP microarrays. PLoS One 4(11): e7862.
6. Binder H, Preibisch S, Berger H (2010) Calibration of microarray gene-expression data. Methods Mol Biol 576: 375-407.
7. Binder H, Wirth H, Galle J (2010) Gene expression density profiles characterize modes of genomic regulation: theory and experiment. J Biotechnol 149(3): 98-114.
8. Binder H, Krohn K, Burden CJ (2010) Washing scaling of GeneChip microarray expression. BMC Bioinformatics 11: 291.
9. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6): 567-578.
10. Bosch FX, Ritter D, Enders C et al (2004) Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value. Int J Cancer 111(4): 530-538.
11. Califano J, Riet P van der, Westra W et al (1996) Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56(11): 2488-2492.
12. Chin D, Boyle GM, Theile DR et al (2004) Molecular introduction to head and neck cancer (HNSCC) carcinogenesis. Br J Plast Surg 57(7): 595-602.
13. Choo AY, Blenis J (2006) TORgeting oncogene addiction for cancer therapy. Cancer Cell 9(2): 77-79.
14. Chuang Han-Yu, Lee Eunjung, Liu Yu-Tsueng et al (2007) Network-based classification of breast cancer metastasis. Mol Syst Biol 3: 140.
15. Dietz A, Boehm A, Horn IS et al (2010) Assay-based response evaluation in head and neck oncology: requirements for better decision making. Eur Arch Otorhinolaryngol 267(4): 483-494.
16. Dietz A, Boehm A, Mozet C et al (2008) Current aspects of targeted therapy in head and neck tumors. Eur Arch Otorhinolaryngol 265(Suppl 1): S 3-12. Review.
17. Dietz A, Boehm A, Reiche A et al (2010) Prediction of outcome of TPF with or without cetuximab induction chemotherapy in head and neck squamous cell carcinoma (HNSCC) using the FLAVINO assay. J Clin Oncol 28: 15 s, (suppl; abstr 5572).
18. Dietz A (Hrsg) (2010) Kopf-Hals-Tumoren - Therapie des Larynx- / Hypopharynxkarzinoms unter besonderer Berücksichtigung des Larynxorganerhalts, 2. Aufl. Unimed-Verlag Bremen.
19. Dutta PR, Maity A (2007) Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 254(2): 165-177. Review.
20. Ein-Dor L, Zuk O, Domany E (2006) Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A 103(15): 5923-5928.
21. Sant M, Allemani C, Santaquilani M et al (2009) EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. EUROCARE Working Group. Eur J Cancer 45(6): 931-991. Epub.
22. Fasold M, Stadler PF, Binder H (2010) G-stack modulated probe intensities on expression arrays - sequence corrections and signal calibration. BMC Bioinformatics 11: 207.
23. Gillison ML (2004) Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 31(6): 744-754. Review.
24. Hardisson D (2003) Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 260(9): 502-508.
25. Hasegawa M, Nelson HH, Peters E et al (2002) Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21(27): 4231-4236.
26. Hay N, Sonenberg N (2004) "Upstream and downstream of mTOR." Genes Dev S 18: 1926-1945.
27. Hewitt RE (2011) Biobanking: the foundation of personalized medicine. Curr Opin Oncol 23: 112-119.
28. Hoffmann S, Otto C, Kurtz S et al (2009) Fast mapping of short sequences with mismatches, insertions and deletions using index structures. PLoS Comput Biol 5(9): e1000502. Epub.
29. Hudes Gary et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281.
30. Johnson WE, Li CW, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes Methods. Biostatistics 8(1): 118-127.
31. Kao KJ, Chang KM, Hsu HC, Huang AT (2011) Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11(1): 143.
32. Läuter J, Horn F, Rosołowski M, Glimm E (2009) High-dimensional data analysis: selection of variables, data compression and graphics-application to gene expression. Biom J 51(2): 235-251.
33. Löffler D, Brocke-Heidrich K, Pfeifer G et al (2007) Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110(4): 1330-1333.
34. Mao L, Hong WK, Papadimitrakopoulou VA (2004) Focus on head and neck cancer. Cancer Cell 5(4): 311-316.
35. Mozet C, Marin DG, Bertolini J et al (2009) Nitric oxide synthase (NOS2 / 3) expression in head and neck squamous cell carcinomas in correlation with clinical patterns. Onkologie 32(11): 655-660.
36. Mozet C, Wichmann G, Tzagkaroulaki L et al (2009) Antagonisten des Hedgehog Signaling Pathways steigern die Zytotoxizität von Cisplatin und Docetaxel gegenüber Kopf-Hals-Plattenepithelkarzinomen (HNSCC). 80. Jahresversammlung der Dtsch Ges. f. Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie, Rostock, 20.-24. 05. 2009. German Medical Science GMS Publishing House, Düsseldorf, Doc09hnod437.
37. Nemunaitis J, Nemunaitis J (2011) Head and neck cancer: response to p53-based therapeutics. Head Neck 33(1): 131-134.
38. Perez-Ordonez B, Beauchemin M, Jordan RC (2006) Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 59(5): 445-453.
39. Posner MR, Lorch JH, Goloubeva O et al (2010) Oropharynx cancer (OPC) in TAX 324: Human papillomavirus (HPV) and survival. Clin Oncol 28: 15 s, (suppl; abstr 5525).
40. Reiche K, Schutt K, Boll K et al (2011) Bioinformatics for RNomics. Methods Mol Biol 719: 299-330.
41. Roesch Ely M, Nees M, Karsai S et al (2005) Transcript and proteome analysis reveals reduced expression of calgranulins in head and neck squamous cell carcinoma. Eur J Cell Biol 84(2-3): 431-444.
42. Roesch-Ely M, Nees M, Karsai S et al (2007) Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene 26(1): 54-64.
43. Roesch-Ely M, Leipold A, Nees M et al (2010) Proteomic analysis of field cancerization in pharynx and oesophagus: a prospective pilot study. J Pathol 221(4): 462-470.
44. Rose D, Hertel J, Reiche K et al (2008) NcDNAlign: plausible multiple alignments of non-protein-coding genomic sequences. Genomics 92(1): 65-74.
45. Schramedei K, Mörbt N, Pfeifer G et al (2011) MicroRNA-21 targets tumor suppressor genes ANP32 A and ARCA4. Oncogene [Epub ahead of print].
46. Schilling MK, Eichenberger M, Maurer CA et al (2002) Long-term survival of patients with stage IV hypopharyngeal cancer: impact of fundus rotation gastroplasty. World J Surg 26(5): 561-565.
47. Seiwert TY, Clement PM, Cupissol D et al (2010) BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study. J Clin Oncol 28: 15 s, (suppl; abstr 5501).
48. Sherr CJ (1996) Cancer cell cycles. Science 274: 1672: 1677.
49. Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102(43): 15545-15550.
50. Veer LJ van't, Dai H, Vijver MJ van de et al (2002) Nature 415: 530-536.
51. Wang Y, Klijn JG, Zhang Y et al (2005) Lancet 365: 671-679.
52. Weber A, Bellmann U, Bootz F et al (2002) INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck. Virchows Arch 441: 133-142.
53. Weber A, Langhanki L, Sommerer F et al (2003) Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 22: 4757-4759.
54. Wolf C, Flechtenmacher C, Dietz A et al (2004) p53-positive tumor distant squamous epithelia of the head and neck reveal selective loss of chromosome 17. Laryngoscope 114(4): 698-704.
55. Zhang J, Chiodini R, Badr A, Zhang G (2011) The impact of next-generation sequencing on genomics. Mol Genet Genomics 38(3): 95-109.